These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 31032968

  • 1. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients.
    Gavva C, Barroso J, Gernsheimer T, Metcalf RA, Warner P, Pagano MB.
    Transfusion; 2019 Jul; 59(7):2276-2281. PubMed ID: 31032968
    [Abstract] [Full Text] [Related]

  • 2. Determination in vivo viability of a transfused platelet product by corrected count increment and percentage platelet response.
    Thuku NW, Shikuku K, Mbugua A.
    Pan Afr Med J; 2017 Jul; 27():226. PubMed ID: 28979628
    [Abstract] [Full Text] [Related]

  • 3. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
    Mirlashari MR, Vetlesen A, Nissen-Meyer LSH, Naper C, Tjønnfjord GE, Njerve IU, Ezligini F, Landmark BF, Meinke S, Sandgren P, Höglund P, Hetland G.
    Transfusion; 2021 Apr; 61(4):1222-1234. PubMed ID: 33580979
    [Abstract] [Full Text] [Related]

  • 4. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
    Wiita AP, Nambiar A.
    Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets.
    Karafin MS, Schumacher C, Zhang J, Simpson P, Johnson ST, Pierce KL.
    Transfusion; 2021 Aug; 61(8):2307-2316. PubMed ID: 34075590
    [Abstract] [Full Text] [Related]

  • 7. A case of platelet transfusion refractoriness due to anti-CD36 with a successful treatment outcome.
    Khatri SS, Curtis BR, Yamada C.
    Immunohematology; 2019 Dec; 35(4):139-144. PubMed ID: 31935329
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation.
    Seike K, Fujii N, Asano N, Ohkuma S, Hirata Y, Fujii K, Sando Y, Nakamura M, Naito K, Saeki K, Meguri Y, Asada N, Ennishi D, Nishimori H, Matsuoka KI, Tsubaki K, Otsuka F, Maeda Y.
    Transfusion; 2020 Mar; 60(3):473-478. PubMed ID: 31970799
    [Abstract] [Full Text] [Related]

  • 10. In vivo efficacy of shipped HLA-matched platelets.
    Haddad SA, Lichtiger B, Klein HG.
    Transfusion; 2006 Aug; 46(8):1306-10. PubMed ID: 16934064
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Recovery, survival, and function of transfused platelets and detection of platelet engraftment after allogeneic stem cell transplantation.
    Vetlesen A, Holme PA, Lyberg T, Kjeldsen-Kragh J.
    Transfusion; 2012 Jun; 52(6):1321-32. PubMed ID: 22084943
    [Abstract] [Full Text] [Related]

  • 17. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
    Figueiredo C, Blaszczyk R.
    J Stem Cells; 2014 Jun; 9(3):149-61. PubMed ID: 25157449
    [Abstract] [Full Text] [Related]

  • 18. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
    Hyun J, Lim YM, Park KD, Han BY, Kim YH, Han KS, Park MH.
    Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
    [Abstract] [Full Text] [Related]

  • 19. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y, Li W, Liu N, Zhang K, Gong Z, Li D, Wang L, Wang D, Jing Y, Wang J, Shan X.
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [Abstract] [Full Text] [Related]

  • 20. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients.
    Friedberg RC, Donnelly SF, Mintz PD.
    Transfusion; 1994 Mar; 34(3):215-20. PubMed ID: 8146893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.